
Equashield Honored as Winner in the 2016 Medical Design Excellence Awards
Equashield has announced that the company's flagship Equashield product has been selected the Gold Winner of the General Hospital Devices and Therapeutic Products category of the 18th Annual Medical Design Excellent Aware competition.
PRESS RELEASE
Port Washington, NY — (June 28, 2016) –
The key innovations that differentiate EQUASHIELD from its competitors, include:
- Built-in pressure equalization within the syringe barrel, eliminating bulky exterior air chambers, a common design feature in most CSTDs on the market;
- Fully encapsulated and sealed syringe, preventing hazardous drug contamination from the back of the syringe, an often overlooked route of exposure common to standard plastic syringes used in competing systems;
- Dry connectors between the syringe, vials and IV bags, ensuring no drug residue escapes the system between transfers.
The Equashield product was recently tested against 5 other Closed Systems across multiple performance tests. The product design characteristics lead to the Equashield system having the best performance data amongst its peers.
The
“We are proud to be recognized as an MDEA Gold Winner this year. Each design decision we have made with EQUASHIELD focuses on the safety and ease-of-use for users. It is critical in this industry that all device makers place safety as the top priority in CSTD design,” said Marino Kriheli, Co-Founder of Equashield. “This is not simply design innovation that results in an intuitive, well-made product. It is about protecting our healthcare workers from hazardous drug exposure to the highest standards.”
The
# # #
About Equashield
Equashield is a leading provider of Closed System Transfer Devices (CSTDs), clinically proven to protect healthcare professionals from hazardous drug exposure. Incorporating a pioneering design, the company’s flagship device, EQUASHIELD® II, covers more routes of exposure than alternative systems by preventing: contamination of syringe plungers, drug residuals on connector surfaces as well as exposure to drug vapor. Studies have shown Equashield’s CSTD to be faster to deploy and easier to use than competing systems. The EQUASHIELD system has been cleared by the FDA under the ONB product code and substantiated in FDA-cleared labeling as preventing microbial ingress for up to seven days.
For more information:
About Medical Design Excellence Awards
The MDEA program is presented by
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.